Page 20 - TD-4-1

Tumor Discovery EpCAM-targeting cancer immunotherapies

38. Bellone S, Black J, English DP, et al. Solitomab, an Samara P. Harnessing the immune system to improve cancer
EpCAM/CD3 bispecific antibody construct (BiTE), is therapy. Ann Transl Med. 2016;4:261.
highly active against primary uterine serous papillary doi: 10.21037/atm.2016.04.01
carcinoma cell lines in vitro. Am J Obstet Gynecol.
2016;214:99.e1-99.e8. 50. Lv Y, Zhang H, Cui Z, et al. Gene delivery to breast cancer by
incorporated EpCAM targeted DARPins into AAV2. BMC
doi: 10.1016/j.ajog.2015.08.011
Cancer. 2023;23:1220.
39. Li D, Guo X, Yang K, et al. EpCAM-targeting CAR-T cell doi: 10.1186/s12885-023-11705-5
immunotherapy is safe and efficacious for epithelial tumors.
Sci Adv. 2023;9:eadg9721. 51. Tavsan Z, Ayar Kayalı H. EpCAM-claudin-tetraspanin-
modulated ovarian cancer progression and drug resistance.
doi: 10.1126/sciadv.adg9721
Cell Adh Migr. 2020;14:57-68.
40. Yu YD, Kim TJ. Chimeric antigen receptor-engineered T doi: 10.1080/19336918.2020.1732761
cell therapy for the management of patients with metastatic
prostate cancer: A comprehensive review. Int J Mol Sci. 52. Ni J, Cozzi P, Beretov J, et al. Epithelial cell adhesion molecule
2021;22:640. (EpCAM) is associated with prostate cancer progression and
chemo-/radio-resistance in vitro and in vivo. BMC Cancer.
doi: 10.3390/ijms22020640
2017;18:2833-2833.
41. Ashley EA. Towards precision medicine. Nat Rev Genet. doi: 10.1158/1538-7445.am2017-2833
2016;17:507-522.
53. Mal A, Bukhari AB, Singh RK, et al. EpCAM-mediated cellular
doi: 10.1038/nrg.2016.86
plasticity promotes radiation resistance and metastasis in
42. Arrowsmith J, Miller P. Trial watch: Phase II and phase III breast cancer. Front Cell Dev Biol. 2021;8:597673.
attrition rates 2011-2012. Nat Rev Drug Discov. 2013;12:569.
doi: 10.3389/fcell.2020.597673
doi: 10.1038/nrd4090
54. Hristodorov D, Amoury M, Mladenov R, et al. EpCAM-
43. Mak IW, Evaniew N, Ghert M. Lost in translation: Animal selective elimination of carcinoma cells by a novel
models and clinical trials in cancer treatment. Am J Transl MAP-based cytolytic fusion protein. Mol Cancer Ther.
Res. 2014;6(2):114-118. 2014;13:2194-2202.
44. Ryaboshapkina M, Hammar M. Tissue-specific genes doi: 10.1158/1535-7163.MCT-13-0781
as an underutilized resource in drug discovery. Sci 55. Qu W, Meng B, Yu Y, Wang S. EpCAM antibody-conjugated
Rep. 2019;9:7233.
mesoporous silica nanoparticles to enhance the anticancer
doi: 10.1038/s41598-019-43829-9 efficacy of carboplatin in retinoblastoma. Mater Sci Eng C.
2017;76:646-651.
45. Nguyen PA, Born DA, Deaton AM, Nioi P, Ward LD.
Phenotypes associated with genes encoding drug targets doi: 10.1016/j.msec.2017.03.036
are predictive of clinical trial side effects. Nat Commun. 56. Kapka-Skrzypczak L, Popek S, Sawicki K, et al. IL-6 prevents
2019;10:1579.
CXCL8-induced stimulation of EpCAM expression in
doi: 10.1038/s41467-019-09407-3 ovarian cancer cells. Mol Med Rep. 2019;19:2317-2322.
46. Sinkala M, Naran K, Ramamurthy D, et al. Machine learning doi: 10.3892/mmr.2019.9890
and bioinformatic analyses link the cell surface receptor 57. Zhang BL, Li D, Gong YL, et al. Preclinical evaluation
transcript levels to the drug response of breast cancer cells of chimeric antigen receptor-modified T cells specific to
and drug off-target effects. PLoS One. 2024;19:e0296511.
epithelial cell adhesion molecule for treating colorectal
doi: 10.1371/journal.pone.0296511 cancer. Hum Gene Ther. 2019;30:402-412.
47. Wayne AS, Fitzgerald DJ, Kreitman RJ, Pastan I. doi: 10.1089/hum.2018.229
Immunotoxins for leukemia. Blood. 2015;123:2470-2478.
58. Zhang Y, Xie X, Yeganeh PN, et al. Immunotherapy for
doi: 10.1182/blood-2014-01-492256.2470 breast cancer using EpCAM aptamer tumor-targeted
gene knockdown. Proc Natl Acad Sci U S A. 2021;118:
48. Morgan RN, Saleh ES, Farrag AH, Aboshanab MK. New
insights on Pseudomonas aeruginosa exotoxin A-based e2022830118.
immunotoxins in targeted cancer therapeutic delivery. Ther doi: 10.1073/pnas.2022830118
Deliv. 2023;14:31-60.
59. Kouba P, Kohout P, Haddadi F, et al. Machine learning-guided
doi: 10.4155/tde-2022-0055 protein engineering. ACS Catal. 2023;13:13863-13895.
49. Papaioannou NE, Beniata OV, Vitsos P, Tsitsilonis O, doi: 10.1021/acscatal.3c02743

Volume 4 Issue 1 (2025) 12 doi: 10.36922/td.4926